Eli Lilly and Company (NYSE: LLY) has nearly halved its stake in United Therapeutics Corp. (Nasdaq: UTHR) to 5.4 percent worth $152.84 million, according to an SEC filing. The Indianapolis-based pharmaceutical company said it owned 3.15 million shares in the Silver Springs-based drug developer, down from 5.25 million shares, representing a 9 percent stake worth $292.53 million last July. The current stake’s value is based on the stock’s closing price of $48.52 per share on Feb. 16.